Recently the number of papers dealing with biological activity study of transitive metals coordination compounds with thiosemicarbazones has increased considerably. It has been established that thiosemicarbazones of aromatic aldehydes, in which the aromatic group forms a unique system with thiosemicarbazone fragment of the molecule, have the highest anticancer effect. This biological activity is connected with their chelating metals from living organisms. Thus, synthesis and investigation of new compounds of biometals with thiosemicarbazones are of great scientific and practical interest. The purpose of this paper is to design optimal synthesis conditions, to determine the composition, probable structure, physico-chemical and anticancer properties of copper(II) coordination compounds with thiosemicarbazones and 4phenylthiosemicarbazones of salicylic aldehyde, of 5-chloro-, 5-bromo-, 5-nitro-, 3,5-dichloro-, 4,5-dibromosalycilic and 2-hydroxi-1-naphtaldehyde. A number of coordination compounds with the following general formulae has been synthesized: Cu(Lig-H)X⋅nH2O and CuA(Lig-2H)⋅nH2O, where Lig = the above mentioned azomethines, X = Cl, Br, NO3, ½ SO4; A = NH3, C5H5N, R-C5H4N (R = CH3, NH2) and sulfanilamides (streptocide, sulphacyl, norsulphazol, ethazol, sulphadimezine, sulphapyridazine: n = 0-6). The composition of the synthesized complex compounds has been determined on the basic of element analysis. The conclusions about probable structure of these complex compounds have been made basing on IR and NMR spectroscopy data, thermal and magnetochemical investigations. Copper(II) salycilidenthiosemicarbazidates with sulphanilamides have polynuclear structure, the rest of the compounds are monomers. In all these substances, thiosemicarbazones act as tridentate-O, N, S mono or double deprotonated ligands. Their thermolysis occurs through three stages: deaquation (70-950C), deamination (145-1950C) and complete decomposition (390-5300C). It has been found that the synthesized compounds inhibit the growth and multiplication process of myeloid human leukemia HL-60 cells in the concentration limits 10-6 – 10-7 mol/l. The researches have been performed with financial support of projects 3C 28, PAS AUF 2001/24.